{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:52:53Z","timestamp":1792079573200,"version":"4.4.0"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1766","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved tezepelumab (Tezspire \u2013 Amgen\/AstraZeneca), a subcutaneously administered thymic stromal lymphopoietin (TSLP) blocker, for add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in patients \u226512 years old. It is the first TSLP blocker to be approved for this indication. Tezepelumab was approved for add-on maintenance treatment of severe asthma in 2021.<\/jats:p>","DOI":"10.58347\/tml.2026.1766b","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:35:46Z","timestamp":1792078546000},"page":"171-173","source":"Crossref","is-referenced-by-count":0,"title":["Tezepelumab (Tezspire) for Nasal Polyps"],"prefix":"10.58347","volume":"68","member":"37151","published-online":{"date-parts":[[2026,10,26]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:35:46Z","timestamp":1792078546000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1766b"}},"subtitle":[],"editor":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,10,26]]},"references-count":0,"journal-issue":{"issue":"1766","published-online":{"date-parts":[[2026,10,26]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2026.1766b","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,26]]}}}